these findings taken together and the ready availability of high doses of recombinant human interleukin 2 substantiate our proposal for initiation of clinical trials using local administration of the interleukin 2 ( bubenik et al . 1983 ) in selected cancer patients .
C0218986
recombinant human interleukin 2
C0021756
interleukin 2